Clinical Concordance for Exclusion of Acute Heart Failure Using the RAMP and Dade Dimension RxL NT-proBNP Assays

M Offner1, E Winckel1, A Jung1, T Lamy2, G Arthur3, ML Zucker3

1Laboratoire de Biochimie Générale et Spécialisée, Hôpital Civil, Strasbourg, France, 2All.DIAG.SA, Strasbourg, France, 3Response Biomedical Corporation, Burnaby, BC, Canada

Introduction

• Accurate evaluation and management of acute dyspnea remains a significant clinical challenge1,2.
• Blood levels of NT-proBNP:
  - are indicative of the degree of heart failure (HF).
  - augment diagnosis and clinical judgment3,4.
  - have been used for risk stratification of patients with acute coronary syndrome and congestive HF5,6.

Results: Method Comparison

• 86 of 91 samples had NT-proBNP levels within the reportable ranges of both test systems (5 - 35,000 pg/mL).

Results: Clinical Concordance

Clinical concordance analysis of the RAMP NT-proBNP and Dade Dimension RxL results using an age independent rule out value of 300 pg/mL.

Conclusions

• The results obtained on the RAMP POC system were comparable to those obtained on the Dade Dimension RxL laboratory analyzer.
• The RAMP NT-proBNP whole blood assay is an accurate clinical indicator that can be used to rule-out acute HF in this population.
• With results available in 15 minutes, RAMP NT-proBNP allows for rapid initiation of appropriate patient treatment.

Bibliography